Back
Compare AU
Compare ESTX vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Euro Stoxx 50 ETF (ESTX) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ESTX | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 112 | 72 |
Median incremental investment | $1,059.33 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,521.72 | $2,328.80 |
Average age group | > 35 | > 35 |
Key Summary
ESTX | CURE | |
|---|---|---|
Strategy | ESTX.AX was created on 2016-07-19 by ETFS. The fund's investment portfolio concentrates primarily on large cap equity. ETFS EURO STOXX 50 ETF (ESTX.AX) aims to provide investors with a return that (before fees and expenses) tracks the performance of the EURO STOXX 50 Index by holding all of the shares that make up the index closely in proportion to their index weights. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ASML Holding NV (9.76 %) Siemens AG (4.56 %) TotalEnergies SE (4.02 %) | Apogee Therapeutics Inc (1.59 %) Erasca Inc (1.42 %) Oruka Therapeutics Inc (1.41 %) |
Top 3 industries | Information Technology (32.54 %) Industrials (26.97 %) Financials (17.62 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Germany (29.66 %) France (29.62 %) Netherlands (18.70 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.35 % | 0.45 % |
Key Summary
ESTX | CURE | |
|---|---|---|
Issuer | ETFS | Global X |
Tracking index | Euro STOXX 50 | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.45 % |
Price | $107.26 | $73.93 |
Size | $480.157 million | $47.526 million |
10Y return | 109.45 % | N/A |
Annual distribution yield (5Y) | 3.67 % | 0.03 % |
Market | ASX | ASX |
First listed date | 21/07/2016 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ESTX | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 112 | 72 |
Median incremental investment | $1,059.33 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,521.72 | $2,328.80 |
Average age group | > 35 | > 35 |
Pros and Cons
ESTX | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ESTX | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |